Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 2/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29862938 | 1.00 | ELANE (0.44) | ELANEPARP1TNKSTNKS2PARP2 | |
| SCHEMBL13783331 | 0.84 | RAD52 (0.51) | ELANEPARP1TNKSTNKS2PARP2 | |
| SCHEMBL21790697 | 0.81 | HRH4 (0.51) | ELANEPARP1TNKSTNKS2PARP2 | |
| SCHEMBL11606052 | 0.81 | HRH4 (0.44) | ELANEPARP1TNKSTNKS2PARP2 | |
| SCHEMBL2916780 | 0.79 | NR4A2 (0.46) | PARP1CYP2A6CYP1A2LMNAMAPT | |
| SCHEMBL29417321 | 0.79 | NR4A2 (0.46) | PARP1CYP2A6CYP1A2LMNAMAPT | |
| SCHEMBL8889479 | 0.78 | ELANE (0.46) | ELANEPARP1TNKSTNKS2PARP2 | |
| SCHEMBL8225421 | 0.76 | PARP1 (0.37) | PARP1TNKSTNKS2KDM4ECYP1A2 | |
| SCHEMBL21230724 | 0.76 | KDM4E (0.32) | KDM4ECYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL12134841 | 0.76 | CYP1A2 (0.44) | PARP1TNKSTNKS2KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-08 | — | — | US | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-1218358-B1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1218358-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-6399603-B1 | QUINAZOLINES; RETARDING APOPTOSIS IN CELLS; INHIBITING CLEAVAGE OF PROTEIN SUBSTRATES BY CASPASE-3; CHEMICAL AND HYDROLYTIC STABILITY | ASTRAZENECA AB (SE) | 2002-06-04 | — | — | US | disclosed |
| WO-2001021598-A1 | THERAPEUTIC QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| WO-1997020822-A1 | QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| US-5064833-A | Substituted quinazoline derivatives for use in gastrointestinal diseases | SMITHKLINE BEECHAM INTERCREDIT B.V. (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0322133-B1 | QUINAZOLINE DERIVATIVES | SmithKline Beecham Intercredit B.V. (NL) | 1991-05-22 | — | — | EP | disclosed |
| EP-0322133-A1 | Quinazoline derivatives | SmithKline Beecham Intercredit B.V. (NL) | 1989-06-28 | — | — | EP | disclosed |
| WO-1989005297-A1 | COMPOUNDS | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1989-06-15 | — | — | WO | disclosed |
| US-4102885-A | Process for preparing 2,4-dihaloquinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262817-A1 | QUINAZOLINE DERIVATIVES TARGETING R(CCUG) REPEATS IN MYOTONIC DYSTROPHY TYPE 2 | MBNL1, HNRNPUL1, HNRNPUL2 | ELANE 3124/4885PARP1 652/4885TNKS 1577/4885 |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ELANE 4267/4885PARP1 1520/4885TNKS 487/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | ELANE 4267/4885PARP1 1520/4885TNKS 487/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ELANE 4267/4885PARP1 1520/4885TNKS 487/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ELANE 4267/4885PARP1 1520/4885TNKS 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.